Efficacy of taxanes rechallenge in first-line treatment of early metastatic relapse of patients with HER2-negative breast cancer previously treated with a (neo)adjuvant taxanes regimen: A multicentre retrospective observational study

BACKGROUND: Taxanes are one of the most effective chemotherapies (CT) in breast cancer (BC), but the efficacy of taxanes rechallenge in early metastatic relapse has been poorly studied in patients previously treated by taxanes in the (neo)adjuvant setting. Our study aimed to analyse the efficacy of...

Descripción completa

Detalles Bibliográficos
Autores principales: Vasseur, Antoine, Carton, Matthieu, Guiu, Severine, Augereau, Paule, Uwer, Lionel, Mouret-Reynier, Marie-Ange, Levy, Christelle, Eymard, Jean-Christophe, Ferrero, Jean-Marc, Leheurteur, Marianne, Goncalves, Anthony, Robert, Marie, De La Motte Rouge, Thibault, Bachelot, Thomas, Petit, Thierry, Debled, Marc, Grinda, Thomas, Desmoulins, Isabelle, Vanlemmens, Laurence, Nicolaï, Vincent, Simon, Gaëtane, Cabel, Luc
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Elsevier 2022
Materias:
Original Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9379666/
https://www.ncbi.nlm.nih.gov/pubmed/35944353
http://dx.doi.org/10.1016/j.breast.2022.07.014

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9379666/
https://www.ncbi.nlm.nih.gov/pubmed/35944353
http://dx.doi.org/10.1016/j.breast.2022.07.014

Ejemplares similares